Home › merck announces
 

Keywords :   


Tag: merck announces

Merck Announces Final Results of Tender Offers for Eight Series of Notes

2014-10-15 14:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (Merck) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the final results of the previously announced offers to purchase (collectively, the Offers) any and all of the outstanding notes listed in the table below (collectively, the Notes). On Oct. 6, 2014, Merck commenced the Offers in accordance with the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 (the Offer to Purchase). Language: English Contact: Merck & Co., Inc.Media:Steve Cragle, (908) 423-3461Lainie Keller, (908) 236-5036orInvestors:Joe Romanelli, (908) 423-5185Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of results final offers

 

Merck Announces Pricing of Tender Offers for Eight Series of Notes

2014-10-15 00:20:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (Merck) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the pricing of the previously announced offers to purchase (collectively, the Offers) any and all of the outstanding notes listed below (collectively, the Notes). The Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 (Offer to Purchase). Language: English Contact: Merck & Co., Inc.Media:Steve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestor Contacts:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of offers series notes

 
 

Merck Announces Proposed Public Debt Offering

2014-10-06 09:24:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (the Company) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of a public offering of three series of Euro denominated senior unsecured notes due 2021, 2026 and 2034 (collectively, the New Notes). The exact terms and timing of the offering will depend upon market conditions and other factors. Language: English Contact: Merck & Co., Inc.Media:Steve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestor:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: public proposed offering debt

 

Merck Announces Tender Offers for Eight Series of Notes

2014-10-06 09:18:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (Merck) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of offers to purchase (collectively, the Offers) any and all of the outstanding notes listed below (collectively, the Notes). The Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 (Offer to Purchase). Language: English Contact: Merck & Co., Inc.MediaSteve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestor:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of offers series notes

 

Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

2014-09-29 11:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced early

 

Sites : [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »